Department of Pharmacy, Yasuda Women's University, 6-13-1 Yasuhigashi, Asaminami-ku, Hiroshima, 731-0152, Japan.
Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Arch Osteoporos. 2021 Jun 30;16(1):106. doi: 10.1007/s11657-021-00968-9.
According to information from the National Health Insurance and Claims database, the risk for hip, radius, and clinical vertebral fractures was higher among patients receiving medication for type 2 diabetes, COPD, or glucocorticoids than among the whole Japanese population after middle age.
The aim of this study was to determine the incidence of fractures among patients receiving medications for type 2 diabetes or chronic obstructive pulmonary disease (COPD) and using glucocorticoids (GC) according to the National Database of Health Insurance Claims (NDB) in Japan.
We obtained data on the number of fractures and patients receiving medications for type 2 diabetes, COPD, or GC from the NDB. The claims data included sex, age group, injury/illness name, hospitalization, outpatient, surgery/medical treatment, and drugs used between January and December 2017.
The risk of hip fracture was higher among patients receiving medications for diabetes or COPD and GC users than in the Japanese population, with standardized incidence ratios (SIRs) of 1.71 (95% confidence interval [CI]1.6-1.75), 1.35 (95% CI 1.28-1.42), and 1.62 (95% CI 1.53-1.71) in men and 1.81 (95% CI 1.79-1.84), 1.67 (95% CI 1.54-1.80), and 1.71 (95% CI 1.66-1.76) in women, respectively. There was also a significantly higher incidence of radial fractures in women and clinical vertebral fractures in both men and women. A greater risk of hip fracture was found among diabetic patients starting in their late 40 s.
Real-world data revealed that the incidence of hip, radius, and clinical vertebral fractures was significantly higher among patients receiving medications for diabetes or COPD and GC users than in the Japanese population after middle age.
根据国家健康保险和理赔数据库的信息,在中年以后,服用 2 型糖尿病、COPD 或糖皮质激素药物的患者发生髋部、桡骨和临床椎体骨折的风险高于日本整个人群。
本研究旨在根据日本国家健康保险索赔数据库(NDB)确定服用 2 型糖尿病或慢性阻塞性肺疾病(COPD)药物且使用糖皮质激素(GC)的患者的骨折发生率。
我们从 NDB 获得了关于骨折数量和服用 2 型糖尿病、COPD 或 GC 药物的患者的数据。索赔数据包括性别、年龄组、损伤/疾病名称、住院、门诊、手术/医疗和 2017 年 1 月至 12 月期间使用的药物。
与日本人群相比,服用糖尿病或 COPD 药物和 GC 使用者的髋部骨折风险更高,男性的标准化发病率比(SIR)分别为 1.71(95%置信区间[CI]1.6-1.75)、1.35(95%CI 1.28-1.42)和 1.62(95%CI 1.53-1.71),女性分别为 1.81(95%CI 1.79-1.84)、1.67(95%CI 1.54-1.80)和 1.71(95%CI 1.66-1.76)。女性桡骨骨折发生率和男女临床椎体骨折发生率均显著升高。女性糖尿病患者在 40 多岁后期开始使用时髋部骨折风险更高。
真实世界的数据显示,与中年以后的日本人群相比,服用糖尿病或 COPD 药物和 GC 药物的患者髋部、桡骨和临床椎体骨折的发生率明显更高。